Loading
BGM0504 / Semaglutide / Type 2 Diabetes (T2DM) · Phase 3 Trial
ClinicalTrials.gov · August 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 3 trial comparing the novel agent BGM0504 to semaglutide in early T2DM with obesity over 52 weeks. No results have been posted to the registry; the record documents planned enrollment, intervention, and primary endpoints only. Readers should await published results before drawing any clinical conclusions.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Type 2 Diabetes (T2DM); age from 18 Years; to 75 Years. Intervention: BGM0504 Injection 15 mg. Compared with: Semaglutide Injection 1.0 mg — Active Comparator. n = 372. 1 site: China.
This is an active Phase 3 trial comparing the novel agent BGM0504 to semaglutide in early T2DM with obesity over 52 weeks. No results have been posted to the registry; the record documents planned enrollment, intervention, and primary endpoints only. Readers should await published results before drawing any clinical conclusions.
Registry record contains no efficacy or safety results; study is actively recruiting.
This trial is not yet reportable for clinical decision-making. Clinicians should monitor for publication of results comparing BGM0504 efficacy and safety to semaglutide in this population.
This is an actively recruiting Phase 3 trial with no results posted; the registry record describes planned design and endpoints only.
As stated by the source record.
Quoted from the source exactly as published.
This trial is not yet reportable for clinical decision-making. Clinicians should monitor for publication of results comparing BGM0504 efficacy and safety to semaglutide in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07743983). This is a study registration, not published results. Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 372 participants (ESTIMATED). Conditions: Type 2 Diabetes (T2DM). Interventions: DRUG: BGM0504; DRUG: semaglutide. Primary outcome measures: Proportion of Participants Achieving HbA1c < 7.0% and Body Weight Reduction ≥ 10% from Baseline , Week 52. Brief summary: This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the rate of diabetes remission at 12 weeks after treatment discontinuation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.